热门资讯> 正文
Ocular Therapeutix股票发行价为4.75亿美元
2025-09-30 19:19
- Ocular Therapeutix (NASDAQ:OCUL) has priced an offering of 37.9M shares at $12.53 each, aiming to raise gross proceeds of around $475.0 million.
- The offering is expected to close on or about October 1, 2025.
- The company expects to use the net proceeds from the sale, together with existing cash, to fund its planned open-label extension study for AXPAXLI in patients with wet age-related macular degeneration (wet AMD); to fund its planned Phase 3 clinical trials of AXPAXLI for the treatment of non-proliferative diabetic retinopathy; for investments in infrastructure, including capital expenditures to support manufacturing; for pre-commercialization activities associated with AXPAXLI, if approved; and for working capital and other general corporate purposes.
- OCUL +4.5% premarket to $13.1
- Source: Press Release
More on Ocular Therapeutix
- Ocular Therapeutix, Inc. (OCUL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
- Ocular Therapeutix: A High-Stakes Bet On Becoming The New Standard Of Care
- Ocular Therapeutix, Inc. (OCUL) Q2 2025 Earnings Call Transcript
- Key deals this week: Ocular Therapeutix, CoreWeave, Air Lease, Cadence and more
- Ocular Therapeutix gains amid takeover speculation (update)
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
